Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX 16:59:25 01/05/2024 BST 5-day change 1st Jan Change
26.46 USD +3.30% Intraday chart for Pfizer, Inc. +0.84% -7.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET DJ
Pfizer lifts profit view on cost cuts RE
Pfizer Plans to Launch Online Platform for COVID-19, Migraine Drugs MT
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET DJ
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
PFIZER INC : UBS remains Neutral ZD
Pfizer Lifts Full-Year 2024 Earnings Outlook Following First-Quarter Beat MT
PFIZER INC : JP Morgan remains Neutral ZD
Pfizer Earnings Top Views; Boosts Full-Year Guidance DJ
Pfizer Q1 Adjusted Earnings, Revenue Decline; 2024 Adjusted Earnings Outlook Lifted -- Shares Gain Pre-Bell MT
Fed Outlook Blunts Wall Street Pre-Bell; Asia, Europe Off MT
Stocks Mostly Down Pre-Bell Ahead of Fed Policy Decision; Asia Churns, Europe Falls MT
Avacta picks Christina Coughlin to replace long-serving CEO AN
PFIZER CEO: RECORDED FAVORABLE ADJUSTMENT TO REVENUES OF $771 M… RE
(PFE) PFIZER Expects Fiscal Year 2024 Revenue Range $58.5B - $61.5B MT
(PFE) PFIZER Expects Fiscal Year 2024 EPS Range $2.15 - $2.35 MT
Earnings Flash (PFE) PFIZER Posts Q1 Revenue $14.88B, vs. Street Est of $13.92B MT
Pfizer beats profit estimates on cost cuts, RSV vaccine sales RE
Earnings Flash (PFE) PFIZER Posts Q1 EPS $0.82, vs. Street Est of $0.51 MT
North American Morning Briefing : Traders Wait for -2- DJ
North American Morning Briefing : Traders Wait for Rate Decision, Powell; AMD Tumbles DJ
Morning Bid: Mayday for bonds as 2024 Fed cut hopes dwindle RE
European Midday Briefing : Fed Awaited With Likelihood Rates Held High For Longer DJ
Sensodyne-maker Haleon posts tepid sales as demand for some products cools off RE
Haleon Pretax Profit Rises Despite Revenue Drop DJ
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
25.62 USD
Average target price
31.62 USD
Spread / Average Target
+23.42%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. BioPharma Credit To Receive Loan Prepayment Following Pfizer's Takeover Of Global Blood Therapeutics